



بسم الله الرحمن الرحيم

∞∞∞∞

تم رفع هذه الرسالة بواسطة / سلوي محمود عقل

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات: لا يوجد



Analytical Investigation of Certain Antidiabetic Drugs

Thesis Presented by

Sarah Elnadi Hassan Elnadi

B.Sc. in Pharmaceutical Sciences, Ain Shams University (2011)

Submitted

for the Partial Fulfillment of the Degree of Master in Pharmaceutical
Sciences

"Pharmaceutical Analytical Chemistry"

Supervised by

Prof. Dr. Maha Farouk Abdel-Ghany

Professor of Pharmaceutical Analytical Chemistry
Faculty of Pharmacy, Ain Shams University

Ass. Prof. Dr. Samah Abdel-Sabour Mohammed

Associate Professor of Pharmaceutical Analytical Chemistry
Egyptian Drug Authority

Dr. Yossra Ahmed Trabik

Lecturer of Pharmaceutical Analytical Chemistry
Faculty of Pharmacy, Ain Shams University

**Pharmaceutical Analytical Chemistry Department
Faculty of Pharmacy-Ain Shams University
(2022)**

Acknowledgment

*First and foremost, praise be to **ALLAH** for this work*

*I would like to express my deepest gratitude and sincere appreciation to **Prof. Dr. Maha Farouk Abdelghany**, Professor of pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University, for her kind and expert supervision, her thoughtful and helpful direction, advice and encouragement throughout this thesis.*

*I would like to express my deepest thanks to **Associate Prof. Dr. Samah Abdel-Sabour Mohammed**, Associate Professor of pharmaceutical Analytical Chemistry, Egyptian drug authority, for her great efforts with me. Her guidance and support nourished my intellectual maturity that I will benefit from for a long time.*

*I would like to express my deepest gratitude and great respect to **Dr. Yossra Ahmed Trabik**, Lecturer of pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University, for her great efforts, keen supervision, continuous support, patience, valuable advice, truthful care, sincere encouragement and her real kind.*

*I would like to express my sincere appreciation to all my colleagues and sisters in **(EDA)** for their friendly cooperation and continuous support. I appreciate their love and care.*

*Also I am deeply grateful to my family and specially my mother (**Dr.Eman**) for their continuous support.*

Sarah ELnadi Hassan

<u>Contents</u>	Page
Contents	i
List of Tables	vii
List of Figures	xii
List of abbreviations	xvi
Preface	xviii
English summary	xx

Part (I)
General Introduction

I.1.Diabetes Mellitus	2
I.2.Main diabetes subtypes	2
I.3.Treatment	3
I.3.1.Insulin and its analogues	3
I.3.2.Oral hypoglycemic drugs	4
I.3.2.1.Sulphonylureas (Insulin secretagogues)	4
I.3.2.2.Biguanides	4
I.3.2.3.Alpha-Glucosidase inhibitors	4
I.3.2.4.Meglitinides	4
I.3.2.5.Thiazolidinediones (Insulin sensitizers)	4
I.3.2.6.Dipeptidyl peptidase 4 inhibitors	4
I.3.2.7.Sodium–glucose cotransporter 2 inhibitors	5
I.4.Studied drugs	6
I.4.1.Metformin Hydrochloride	6
I.4.2.Canagliflozin	7
I.4.3.Empagliflozin	8
I.4.4.Dapagliflozin	9
I.5.Literature review of the studied drugs	10
I.5.1.Chromatographic methods for the studied drugs	10
I.5.1.1.HPLC methods	10
I.5.1.2.TLC methods	21
I.5.2.Spectroscopic methods	26
I.5.2.1.Spectrophotometric methods	26
I.5.2.2.Spectrofluorimetric methods	29

I.5.2.3.FTIR methods	31
I.5.3.Electrochemical methods	31
I.5.4.CE methods	34

PART (II)

**Spectroscopic methods for determination of the
studied drugs**

Section (A)

**Stability indicating spectrophotometric methods for
simultaneous determination of Metformin Hydrochloride
and Canagliflozin in the presence of Canagliflozin complete
oxidative degradation product**

II.A.1.Introduction	38
II.A.2.Experimental	40
II.A.2.1.Instrumentation	40
II.A.2.2.Pure samples and pharmaceutical formulation	40
II.A.2.3.Chemicals and reagents	41
II.A.2.4.Standard solutions	41
II.A.2.5.Preparation of calibration curves	41
II.A.2.6.Forced degradation studies	41
II.A.2.7.Preparation of pharmaceutical samples	42
II.A.2.8.Preparation of laboratory prepared mixtures	43
II.A.2.9.Procedures	43
II.A.2.9.1.Spectral characteristics of CANA, MET and CANAD	43
II.A.2.9.2.Method validation	44
II.A.3.Results and discussion	46
II.A.3.1.Method development	48
II.A.3.2.Method validation	49
II.A.3.3.Pharmaceutical dosage forms & standard addition technique	50
II.A.3.4.Statistical analysis	51

Section (B)

**Spectrophotometric methods for simultaneous
determination of Metformin Hydrochloride, Empagliflozin
and Canagliflozin in their ternary mixture**

II.B.1.Introduction	79
II.B.2.Experimental	80
II.B.2.1.Instrumentation	80
II.B.2.2.Pure samples and pharmaceutical formulation	80
II.B.2.3.Chemicals and reagents	80
II.B.2.4.Standard solutions	80
II.B.2.5.Preparation of calibration curves	81
II.B.2.6.Preparation of pharmaceutical samples	81
II.B.2.7.Preparation of laboratory prepared mixtures	81
II.B.2.8.Procedures	81
II.B.2.8.1.Spectral characteristics and wavelength selection	82
II.B.2.8.2.Method validation	83
II.B.3.Results and discussion	85
II.B.3.1.Method development	86
II.B.3.2.Method validation	87
II.B.3.3.Pharmaceutical dosage forms & standard addition technique	89
II.B.3.4.Statistical analysis	90

Section (C)

**A green Fourier Transform Infrared Spectroscopy for
determination of Canagliflozin using potassium bromide
disc technique**

II.C.1.Introduction	118
II.C.2.Experimental	118
II.C.2.1.Instrumentation	118
II.C.2.2.Pure samples and pharmaceutical formulation	118
II.C.2.3.Chemicals and reagents	119
II.C.2.4.Stock standard	119
II.C.2.5.Preparation of calibration curve	119

[Contents]

II.C.2.6. Preparation of pharmaceutical samples	119
II.C.2.7.Procedures	119
II.C. 2.7.1.Selection of analytical wave number	119
II.C. 2.7.2.Method validation	120
II.C.3.Results and discussion	121
II.C.3.1.Method development	121
II.C.3.2.Method validation	122
II.C.3.3.Pharmaceutical dosage form& standard addition technique	123
II.C.3.4.Statistical analysis	123
II.C.3.5.Assessment of the green nature of the proposed method	123

Section (D)

Synchronous spectrofluorimetric determination of Canagliflozin

II.D.1.Introduction	134
II.D.2.Experimental	134
II.D.2.1.Instrumentation	134
II.D.2.2.Pure samples and pharmaceutical formulation	134
II.D.2.3.Chemicals and reagents	134
II.D.2.4.Standard solutions	135
II.D.2.5.Preparation of calibration curves	135
II.D.2.6.Preparation of pharmaceutical samples	135
II.D.2.7.Preparation of placebo	136
II.D.2.8.Procedures	136
II.D.2.8.1.Synchronous spectrofluorimetric procedure	136
II.D.2.8.2.Method validation	136
II.D.3.Results and discussion	138
II.D.3.1.Method development	138
II.D.3.2.Method validation	140
II.D.3.3.Pharmaceutical dosage forms & standard addition technique	141
II.D.3.4.Uniformity of dosage unit by weight variation	141

II.D.3.5.Statistical analysis	141
-------------------------------	-----

PART (III)

Stability indicating method for simultaneous determination of Metformin Hydrochloride, Empagliflozin, Dapagliflozin and Canagliflozin in the presence of Metformin Hydrochloride complete oxidative degradation product by High Performance Liquid Chromatography

III.1.Introduction	158
III.2.Experimental	158
III.2.1.Instrumentation	158
III.2.2.Pure samples and pharmaceutical formulation	159
III.2.3.Chemicals and reagents	159
III.2.4.Preparation of mobile phase	159
III.2.5.Preparation of diluent	159
III.2.6.Stock standard solutions	159
III.2.7.Preparation of calibration curves	159
III.2.8.Forced degradation studies	160
III.2.9.Preparation of pharmaceutical samples	161
III.2.10.Procedures	161
III.2.10.1.Chromatographic conditions	161
III.2.10.2.Method validation	161
III.3.Results and discussion	164
III.3.1.Method development	164
III.3.2.Method validation	165
III.3.3.Pharmaceutical dosage forms & standard addition technique	167
III.3.4.Statistical analysis	167

PART (IV)

Simultaneous determination of Metformin Hydrochloride and Canagliflozin by Capillary electrophoresis: An application to a green approach

[Contents]

IV.1.Introduction	186
IV.2. Experimental	187
IV.2.1.Instrumentation	187
IV.2.2.Pure samples and pharmaceutical formulation	188
IV.2.3.Chemicals and reagents	188
IV.2.4.Standard solutions	188
IV.2.5.Preparation of calibration curves	188
IV.2.6. preparation of pharmaceutical sample	189
IV.2.7.Procedures	189
IV.2.7.1.Method parameters	189
IV.2.7.2.Method validation	189
IV.3.Results and discussion	191
IV.3.1.Separation conditions' optimization	191
IV.3.2.Factors affects electrophoretic separation	192
IV.3.3.Method validation	192
IV.3.4.Pharmaceutical dosage forms & standard addition technique	194
IV.3.5.Statistical analysis	194
IV.3.6.Assessment of the green nature of the proposed method	194

Part (V)

General Discussion	205
References	214

List of tables

Table No.	Table title	Page No.
1	HPLC methods for the studied drugs	10
2	TLC methods for the studied drugs	21
3	Results of assay validation parameters of DD method for the determination of CANA & MET in bulk powder	68
4	Results of assay validation parameters of MCR method for the determination of CANA & MET in bulk powder	69
5	Determination of CANA & MET in bulk powder by the proposed DD method	70
6	Determination of CANA & MET in bulk powder by the proposed MCR method	71
7	Determination of CANA & MET in laboratory prepared mixtures with CANAD by the proposed DD method	72
8	Determination of CANA & MET in laboratory prepared mixtures with CANAD by the proposed MCR method	73
9	Determination of CANA & MET in pharmaceutical formulation by the proposed DD method & application of standard addition technique	74
10	Determination of CANA & MET in the pharmaceutical formulations by the proposed MCR method & application of standard addition technique	75
11	Statistical comparison between the results of the proposed DD method & reported method for determination of CANA & MET	76

[List of Tables]

12	Statistical comparison between the results of the proposed MCR method & reported method for determination of CANA & MET	77
13	Results of assay validation parameters for the determination of MET, EMPA by the proposed MCR method & for the determination of CANA directly at zero order in their bulk powder	105
14	Results of assay validation parameters of MCDD method for the determination of MET & EMPA in bulk powder	106
15	Determination of MET, EMPA by the proposed MCR method & determination of CANA directly at zero order in their bulk powder	107
16	Determination of MET & EMPA in bulk powder by the proposed MCDD method	108
17	Determination of MET, EMPA by the proposed MCR method & determination of CANA directly at zero order in their laboratory prepared mixtures	109
18	Determination of MET & EMPA by the proposed MCDD method in their laboratory prepared mixtures with CANA	110
19	Determination of MET in pharmaceutical formulation by the proposed MCR method & application of standard addition technique	111
20	Determination of MET in pharmaceutical formulation by the proposed MCDD method & application of standard addition technique	112
21	Determination of EMPA in pharmaceutical formulation by the proposed MCR & MCDD methods using standard spiking technique	113
22	Determination of CANA in pharmaceutical formulation by the proposed zero order method & application of standard addition technique	114

[List of Tables]

23	Statistical comparison between the results of determination of MET, EMPA by the proposed MCR, determination of CANA directly at zero order & reported method	115
24	Statistical comparison between the results of the proposed MCDD method & reported method for determination of MET and EMPA	116
25	Results of assay validation parameters of FTIR method for the determination of CANA in bulk powder	128
26	Determination of CANA in bulk powder by the proposed FTIR method	129
27	Determination of CANA in pharmaceutical formulation by the proposed FTIR method & application of standard addition technique	130
28	Statistical comparison between the results of the proposed FTIR method & reported method for determination of CANA in pharmaceutical formulation	131
29	Analytical Eco-scale assessment of the proposed FTIR method	132
30	Study of solvent effect of water, acetonitrile and methanol; separately in synchronous mode for the determination of CANA in bulk powder by studying linearity parameters	151
31	Results of assay validation parameters of Spectrofluorimetric method for the determination of CANA in bulk powder	152
32	Determination of CANA in bulk powder by the proposed method	153
33	Determination of CANA in pharmaceutical formulation by the proposed spectrofluorimetric method & application of standard addition technique	154

[List of Tables]

34	Results of uniformity of dosage unit of invokana [®] film coated tablets by weight variation using the proposed method	155
35	Statistical comparison between the results of the proposed spectrofluorimetric method & reported method for determination of CANA	156
36	Chromatographic conditions of HPLC for simultaneous determination of MET, EMPA, DAPA & CANA	177
37	Results of assay validation parameters of HPLC method for the determination of MET, EMPA, DAPA & CANA in bulk powder	178
38	Determination of MET, EMPA, DAPA & CANA in bulk powder by the proposed HPLC method	179
39	Study of robustness of the developed HPLC method	180
40	System suitability parameters of the proposed HPLC method	181
41	Determination of MET & EMPA in pharmaceutical formulation by the proposed method & application of standard addition technique	182
42	Determination of DAPA & CANA in pharmaceutical formulation by the proposed method & application of standard addition technique	183
43	Statistical comparison between the results of the proposed method and reported method for determination of MET, EMPA, DAPA & CANA	184
44	Results of assay Validation parameters of CE method for the determination of CANA and MET in bulk powder	199
45	Determination of MET and CANA in bulk powder by the proposed CE method	200

[List of Tables]

46	Determination of CANA & MET in pharmaceutical formulation by the proposed CE & application of standard addition technique	201
47	Statistical comparison between the results of the proposed CE method & reported method for determination of MET & CANA	202
48	Analytical Eco-scale assessment of the proposed capillary electrophoresis method	203
49	Statistical comparison between the proposed methods & the reported method for determination of MET	210
50	Statistical comparison between the proposed methods & the reported method for determination of CANA	211
51	Statistical comparison between the proposed methods & the reported method for determination of EMPA	212

List of figures

Fig No	Figure caption	Page No
1	Chemical structure of Metformin Hydrochloride.	6
2	Chemical structure of Canagliflozin.	7
3	Chemical structure of Empagliflozin.	8
4	Chemical structure of Dapagliflozin.	9
5	Graphical representation of assessing CANA forced degradation study by the reported HPLC method.	52
6	Zero order UV absorption spectra of standard solutions of CANA, MET, CANAD & their laboratory prepared mixture.	53
7	Ratio spectra of CANA using CANAD divisor.	54
8	Ratio spectra of MET using CANAD divisor.	55
9	Second derivative of ratio spectra of CANA using CANAD divisor.	56
10	First derivative of ratio spectra of MET using CANAD divisor.	57
11	Second derivative of ratio spectra of CANA & MET using CANAD, showing zero-crossing point of MET.	58
12	First derivative of ratio spectra of MET & CANA using CANAD, showing zero-crossing point of CANA.	59
13	Ratio spectra of CANA using CANAD divisor.	60
14	MCR spectra of CANA using CANAD divisor.	61
15	Ratio spectra of different concentration of MET using CANAD divisor.	62
16	MCR spectra of MET using CANAD & CANA divisors.	63
17	Linearity of peak amplitudes of DD^2 to the corresponding concentrations of CANA using CANAD divisor.	64
18	Linearity of peak amplitudes of DD^1 to the corresponding MET concentrations using CANAD divisor.	65